Otsuka's Kidney Drug Maintains Function in Late-Stage Trial

• Trial involved 320 participants with primary IgA nephropathy; drug recipients showed increased estimated glomerular filtration rate (eGFR) while placebo group experienced decline
• Voyxact is a monoclonal antibody administered every four weeks with at-home convenience option; Otsuka has begun rolling FDA submission for traditional approval based on 24-month data
• IgA nephropathy occurs when immunoglobulin A antibodies build up in kidneys causing inflammation and potential organ failure; competitors Vera Therapeutics and Vertex Pharmaceuticals are also developing treatments

Summary: Otsuka's Kidney Drug Shows Promise in IgA Nephropathy Trial

Key Development: Otsuka Pharmaceutical announced positive results from a late-stage clinical trial of Voyxact (sibeprenlimab), demonstrating the drug's ability to preserve kidney function in patients with primary immunoglobulin A (IgA) nephropathy over 12 months.

Trial Details: The study enrolled 320 participants and measured efficacy using estimated glomerular filtration rate (eGFR), a key indicator of kidney filtering capability. Patients receiving Voyxact showed increased kidney function, while the placebo group experienced decline. The drug successfully reduced proteinuria, a common symptom of the autoimmune disease.

Disease Background: IgA nephropathy occurs when immunoglobulin A antibodies accumulate in kidneys, causing inflammation and tissue damage that can lead to kidney failure. The condition results in blood and protein leaking into urine.

Product Specifications: Voyxact is a monoclonal antibody administered every four weeks, either by caregivers or patients themselves, offering at-home treatment convenience.

Timeline: Otsuka expects 24-month data from the trial within two months (by August). The company has initiated a rolling submission to the U.S. FDA for traditional approval based on the 24-month results.

Market Context: Otsuka faces competition in the IgA nephropathy treatment space from Vera Therapeutics and Vertex Pharmaceuticals, both developing rival therapies.

Clinical Significance: Chief Medical Officer John Kraus emphasized the encouraging eGFR stability and confirmed that proteinuria reduction successfully translated into preserved kidney function, providing early evidence the drug may slow disease progression.

Investment Implications: Positive results position Otsuka competitively in the growing nephrology market, with potential FDA approval on the horizon.